Robert C. Green

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Robert C. Green
Robert C. Green headshot.jpg
Alma materAmherst College
University of Virginia School of Medicine
Emory University
Scientific career
InstitutionsBrigham and Women's Hospital
Harvard Medical School

Robert C. Green is an American medical geneticist, physician, and public health researcher. He directs the Genomes2People Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School. Research led by Green includes clinical and research aspects of genomic medicine, including the development and disclosure of Alzheimer's disease risk estimates (the REVEAL Study)[1][2] and one of the first prospective studies of direct-to-consumer genetic testing services (the PGen Study).[3] He is researching the implementation of medical sequencing in adults (the MedSeq Project) and newborns (the BabySeq Project).[4][5][6]


Green was born in Richmond, Virginia, and attended Amherst College,[7] the University of Virginia School of Medicine,[8] and earned a Masters of Public Health in Epidemiology from Emory University School of Public Health. He completed a residency in neurology at Harvard Medical School’s Longwood Neurology Program, and research fellowships at Beth Israel Deaconess Medical Center and Boston Children’s Hospital. Green is board-certified in neurology and medical genetics. He was previously on the faculty at Emory University School of Medicine (1988-1996) and the Boston University School of Medicine (1999-2011).[9]

Genomic Research Projects and Contributions[edit]

Since 1999, Green has served as Principal Investigator of the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study,[10] which explores the behavioral, and health-related impact of disclosing genetic risk for Alzheimer’s disease. The study is a series of multi-site, randomized, controlled clinical trials that provide empirical data to address ethical, social and translational issues in genetic susceptibility testing for common diseases.[11][12]

Green also co-led (with J. Scott Roberts, Ph.D.) the Impact of Personal Genomics (PGen) Study, one of the first to investigate the characteristics of consumers; the behavioral and health impact; and the translational and social issues associated with personal genomic testing services.[13] He helped develop the American College of Medical Genetics and Genomics (ACMG)’s controversial recommendations for reporting incidental findings in clinical exome and genome sequencing.[14] Green also contributed to the design of a variant classification pipeline,[15] and a single page summary for reporting clinically relevant results of whole genome sequencing to physicians.[16][17]

Professional Affiliations and Awards[edit]

Green is Associate Director for Research of Partners HealthCare Personalized Medicine and a member of the Executive Committee for the Partners BioBank. He is a Board Member of the Council for Responsible Genetics.[18] He co-chairs the Steering Committee of the NIH Consortium in Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT).[19] Green is a member of the Consortium on Electronic Medical Records and Genomics (eMERGE).[20] He serves on the Institute of Medicine Committee on the "Evidence Base for Genetic Testing," and has collaborated on research studies with Illumina (company), 23andMe, Pathway and Google.[21][22][23]

Green received the 2014 Coriell Award for Scientific Achievement in Personalized Medicine.[24]


  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^
  9. ^
  10. ^
  11. ^
  12. ^
  13. ^
  14. ^
  15. ^ Lee In-Hee. "Prioritizing Disease-Linked Variants, Genes, and Pathways with an Interactive Whole-Genome Analysis Pipeline". Human Mutation. 35: 537–547. doi:10.1002/humu.22520. PMC 4130156.
  16. ^
  17. ^
  18. ^
  19. ^
  20. ^
  21. ^
  22. ^
  23. ^
  24. ^